Jagsonpal Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Wed Apr 22 2026

Jagsonpal Pharmaceuticals (JAGSONPAL) Q4 FY26 results are expected on May 2026. Analyst consensus estimates revenue at Rs 145–170 Cr and PAT at Rs 15–21 Cr for the January to March 2026 quarter. This article covers what analysts are expecting, five key growth factors to watch, risks to the investment thesis, and a complete FAQ section for investors.

Click Here — Get Free SEBI-registered Research on Jagsonpal Pharmaceuticals on Univest.

Table of Contents

Jagsonpal Pharmaceuticals Q4 FY26 Results Overview

Company	Jagsonpal Pharmaceuticals
NSE Ticker	JAGSONPAL
Sector	Pharma / Domestic Branded
CMP (April 2026)	Rs 265
52-Week High	Rs 420
52-Week Low	Rs 205
Q4 FY26 Results Date	May 2026
Revenue Estimate	Rs 145–170 Cr
PAT Estimate	Rs 15–21 Cr
Key Margin Metric	EBITDA 13–16%

Data from NSE/BSE and analyst estimates. April 2026. Verify before investing.

Track live Jagsonpal Pharmaceuticals price and analyst targets on the Univest Screener.

What to Expect from Jagsonpal Pharmaceuticals Q4 FY26

Get Free Investment Predictions on Univest — Tap Here.

Jagsonpal Pharmaceuticals is expected to report Q4 FY26 results on May 2026. The board meeting will consider the financial results for the quarter ended March 31, 2026. Revenue is estimated at Rs 145–170 Cr and PAT at Rs 15–21 Cr, with EBITDA 13–16% as the key operational metric. India’s Q4 FY26 earnings season runs through April and May 2026, with the Nifty 50 aggregate PAT growth expected at 8 to 12 percent YoY. Key themes across the season include margin recovery, capex normalisation, and FY27 guidance.

Budget 2026-27 Impact on Pharma

Union Budget 2026-27 continued strong support for the Pharma sector through PLI scheme continuation, infrastructure capex of Rs 11.21 lakh crore, and consumption-led demand incentives. The US 26 percent reciprocal tariff announced April 2, 2026 has created FII outflow pressure across Indian equities, but domestic policy support provides a buffer for Jagsonpal Pharmaceuticals’s core business segments heading into Q4 FY26.

Q4 FY26 Estimates Table

Metric	Q4 FY26 Estimate	Q4 FY25 Actual	YoY Change
Revenue	Rs 145–170 Cr	Verify on NSE	10–15% YoY est
PAT	Rs 15–21 Cr	Verify on NSE	12–18% YoY est
EBITDA	EBITDA 13–16%	Verify on NSE	Stable to improving

Estimates from analyst consensus. Actual results may differ. Verify before investing.

5 Key Growth Factors to Watch in Jagsonpal Pharmaceuticals Q4 FY26 Results

1. US Generics Revenue and Market Share

Analysts tracking Jagsonpal Pharmaceuticals will monitor US Generics Revenue and Market Share closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

2. Domestic Branded Formulations Volume

Analysts tracking Jagsonpal Pharmaceuticals will monitor Domestic Branded Formulations Volume closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

3. API Business Margin Recovery

Analysts tracking Jagsonpal Pharmaceuticals will monitor API Business Margin Recovery closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

4. FDA Inspection Status

Analysts tracking Jagsonpal Pharmaceuticals will monitor FDA Inspection Status closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

5. R&D Pipeline and ANDA Filings

Analysts tracking Jagsonpal Pharmaceuticals will monitor R&D Pipeline and ANDA Filings closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

Download the Univest iOS App or Android App for live Q4 FY26 results alerts and SEBI-registered analyst research on Jagsonpal Pharmaceuticals.

5 Risk Factors for Jagsonpal Pharmaceuticals Investors

1. FDA Warning Letter or Import Alert Risk

FDA Warning Letter or Import Alert Risk is a key monitorable for Jagsonpal Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

2. US Generics Price Erosion — 5 to 8 percent Annual

US Generics Price Erosion — 5 to 8 percent Annual is a key monitorable for Jagsonpal Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

3. R&D Pipeline Failure or Delay

R&D Pipeline Failure or Delay is a key monitorable for Jagsonpal Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

4. Emerging Market Currency Volatility

Emerging Market Currency Volatility is a key monitorable for Jagsonpal Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

5. Domestic Pricing Regulation — DPCO

Domestic Pricing Regulation — DPCO is a key monitorable for Jagsonpal Pharmaceuticals investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

Analyst Ratings and Targets for Jagsonpal Pharmaceuticals

Brokerage	Rating	12M Target	Thesis
MOFSL	Buy	Rs 318	FY27 earnings recovery; Pharma sector leadership
YES Securities	Buy	Rs 323	Quality execution; accumulate at support
Kotak Institutional	Add	Rs 304	Monitor Q4 FY26 result vs estimates closely
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity

Analyst targets are estimates as of April 2026. These are not guaranteed returns. Verify before investing.

Subscribe to Univest Pro for SEBI-registered analyst entry, target, and stop-loss recommendations.

Q4 FY26 Earnings Calendar — Other Major Companies

Company	Results Date
Infosys	Apr 23, 2026
IndusInd Bank	Apr 24, 2026
InterGlobe Aviation (IndiGo)	Apr 28, 2026
Jagsonpal Pharmaceuticals	May 2026

For the full Q4 FY26 results calendar, visit Univest Blogs.

Discover Pharma stocks with strong Q4 FY26 performance on the Univest Screener.

Conclusion

Jagsonpal Pharmaceuticals (JAGSONPAL) Q4 FY26 results on May 2026 are a key earnings event for investors in the Pharma / Domestic Branded sector. Analyst consensus expects revenue of Rs 145–170 Cr and PAT of Rs 15–21 Cr. A beat versus estimates supports the bull case for re-rating toward analyst targets. A miss increases downside risk. Monitor results live and get instant research alerts on the Univest Screener or the Univest App. For more Q4 FY26 results previews, visit Univest Blogs.

Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. All analyst estimates and targets are sourced from publicly available research and may change. Verify all numbers on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: When is Jagsonpal Pharmaceuticals Q4 FY26 results date?

Jagsonpal Pharmaceuticals Q4 FY26 results are expected on May 2026. The board meeting will consider the quarterly financials for January to March 2026. Track the announcement on NSE or the Univest Screener.

Q: What is Jagsonpal Pharmaceuticals Q4 FY26 revenue estimate?

Analyst consensus estimates Jagsonpal Pharmaceuticals Q4 FY26 revenue at Rs 145–170 Cr. Actual results may differ. Verify with MOFSL, YES Securities, or Kotak research once declared on May 2026.

Q: What is Jagsonpal Pharmaceuticals Q4 FY26 PAT estimate?

Analyst consensus expects Jagsonpal Pharmaceuticals Q4 FY26 PAT at Rs 15–21 Cr. This is an estimate based on publicly available research — actual results may vary. Track results live on the Univest Screener.

Q: Is Jagsonpal Pharmaceuticals a buy before Q4 FY26 results?

This article does not constitute investment advice. Investors should review actual Q4 FY26 results before making investment decisions. A beat versus estimates typically supports price recovery; a miss increases downside risk. Consult a SEBI-registered financial advisor.

Q: What is Jagsonpal Pharmaceuticals current share price?

Jagsonpal Pharmaceuticals (NSE: JAGSONPAL) is trading at Rs 265 as of April 2026. Track the live price, FII or DII flows, and analyst ratings on the Univest Screener at univest.in/screeners.

Q: What are the key factors to watch in Jagsonpal Pharmaceuticals Q4 FY26?

Key factors for Jagsonpal Pharmaceuticals Q4 FY26 include: US Generics Revenue and Market Share, Domestic Branded Formulations Volume, API Business Margin Recovery. Track all these metrics on the Univest Screener.

Q: What is Jagsonpal Pharmaceuticals FY27 outlook?

Analyst consensus expects Jagsonpal Pharmaceuticals to deliver 12 to 18 percent earnings growth in FY27 — contingent on macro stabilisation, sector tailwinds, and execution on the growth plan outlined in Q4 FY26 management commentary.

Q: Where to track Jagsonpal Pharmaceuticals Q4 FY26 results live?

Track Jagsonpal Pharmaceuticals Q4 FY26 results live on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for instant research alerts when results are declared on May 2026.